Table 2 Work impairment in patients with PsA, assessed through mean WPAI scores at baseline
Study name | Mean score at baseline % (SD) | |||||||
|---|---|---|---|---|---|---|---|---|
N | Absenteeism | N | Presenteeism | N | Work productivity | N | Activity impairment | |
Adalimumab 40Â mg | ||||||||
 Nakagawa 2019 [33] | 106 | 8.4 | 106 | 37.5 | 106 | 40.2 | 104 | 41.7 |
 SELECT-PsA 1 2021 [22] | 243 | 12.8 (26.4) | 230 | 38.3 (24.4) | 243 | 44.8 (28.8) | 429 | 49.3 (25.9) |
101 | 8.7 (21.4) | 101 | 37.3 (24.5) | 101 | 40.6 (25.2) | 101 | 46.9 (26.0) | |
 BE OPTIMAL 2022 (data on file) | 90 | 5.8 (19.4) | 87 | 34.1 (25.5) | 87 | 35.3 (26.3) | 140 | 45.5 (23.5) |
Bimekizumab 160Â mg | ||||||||
 BE OPTIMAL 2022 (data on file) | 270 | 7.7 (21.4) | 262 | 34.8 (25.7) | 262 | 37.0 (27.2) | 430 | 43.2 (24.4) |
Ixekizumab 80Â mg | ||||||||
107 | 9.2 (21.0) | 107 | 40.0 (26.7) | 107 | 42.3 (28.5) | 107 | 47.9 (26.3) | |
103 | 7.7 (23.0) | 103 | 35.8 (21.6) | 103 | 37.4 (21.6) | 103 | 47.1 (23.4) | |
122 | 11.6 (26.6) | 122 | 45.0 (25.7) | 122 | 46.9 (26.7) | 122 | 53.9 (24.9) | |
123 | 8.8 (23.2) | 123 | 36.9 (25.0) | 123 | 38.8 (26.6) | 123 | 49.3 (26.5) | |
Risankizumab 150Â mg | ||||||||
 KEEPsAKE 1 2022 [23] | 265 | 15.4 (28.6) | 249 | 42.7 (25.5) | 265 | 49.9 (29.9) | 482 | 52.6 (25.1) |
 KEEPsAKE 2 2022 [24] | 127 | 12.4 (24.1) | 123 | 41.3 (26.0) | 127 | 47.4 (28.9) | 224 | 50.5 (26.6) |
Secukinumab 150Â mg | ||||||||
 FUTURE 1 2017 [28] | 94 | 15.0 (28.4) | 88 | 40.1 (26.7) | 89 | 47.0 (29.8) | 195 | 50.9 (26.4) |
 FUTURE 2 2015 [32] | 60 | 7.0 (15.5) | 61 | 37.1 (26.4) | 60 | 39.1 (28.2) | 99 | 48.8 (26.5) |
Secukinumab 300Â mg | ||||||||
 Corrona 2020 [21] | 51 | 14.4 | 58 | 30.5 | 51 | 40.7 | 89 | 42.7 |
 FUTURE 2 2015 [32] | 63 | 17.0 (27.6) | 59 | 38.1 (25.6) | 59 | 42.7 (28.7) | 99 | 51.0 (24.8) |
Upadacitinib 15Â mg | ||||||||
 SELECT-PsA 1 2021 [22] | 251 | 11.7 (24.5) | 240 | 43.0 (25.6) | 251 | 48.3 (29) | 429 | 52.0 (25.2) |
 SELECT-PsA 2 2021 [27] | 120 | 15.8 (29.1) | 113 | 41.1 (24.4) | 120 | 48.5 (29.6) | 211 | 52.0 (26.1) |
Placebo | ||||||||
 FUTURE 1 2017 [28] | 108 | 15.2 (26.6) | 107 | 47.3 (28.9) | 105 | 47.3 (28.9) | 199 | 51.3 (26.4) |
 FUTURE 2 2015 [32] | 59 | 12.4 (27.0) | 57 | 32.5 (23.0) | 55 | 35.4 (24.9) | 98 | 45.1 (27.4) |
 SELECT-PsA 1 2021 [22] | 241 | 16.3 (28.2) | 241 | 43.6 (24.8) | 241 | 50.8 (29.0) | 423 | 49.6 (25.0) |
 SELECT-PsA 2 2021 [27] | 100 | 16.3 (27.5) | 95 | 41.9 (27.3) | 100 | 49.4 (31.5) | 212 | 55.1 (26.5) |
106 | 8.9 (24.5) | 106 | 32.4 (21.2) | 106 | 34.6 (23.4) | 106 | 46.1 (24.7) | |
118 | 11.9 (28.1) | 118 | 40.4 (28.8) | 118 | 41.5 (29.6) | 118 | 54.0 (25.8) | |
 KEEPsAKE 1 2022 [22] | 251 | 12.1 (24.9) | 237 | 39.9 (24.0) | 251 | 46.6 (27.7) | 477 | 52.0 (24.4) |
 KEEPsAKE 2 2022 [24] | 136 | 11.8 (23.5) | 131 | 45.1 (24.2) | 136 | 50.1 (27.6) | 219 | 51.6 (25.7) |
 BE OPTIMAL 2022 (data on file) | 189 | 8.5 (22.1) | 181 | 32.3 (24.7) | 181 | 34.2 (26.3) | 281 | 43.2 (24.5) |